Swedish Orphan Biovitrum

This study tested whether a drug called pegcetacoplan could help people with cold agglutinin disease, a rare condition where the immune system attacks red blood cells. It involved 24 adults who received either the drug or a placebo via twice-weekly injections at home for 24 weeks…

This study tested an experimental injection called SEL-212 for people with chronic gout that doesn't get better with standard medications. About 112 participants received either the drug or a placebo shot every month for six months. The main goal was to see if the treatment could…

This study observed how patients with hemophilia B used the extended-release clotting factor Alprolix in real-world settings over two years. Researchers tracked bleeding rates, injection frequency, and medication usage in 151 patients who were already prescribed this treatment. T…

This study tested the safety and effectiveness of the drug emapalumab in Chinese patients with primary hemophagocytic lymphohistiocytosis (pHLH), a rare and serious immune system disorder. The 13 participants had already tried other standard treatments without sufficient success.…

This study tested an experimental drug called SEL-212 for people with chronic gout that doesn't respond to usual medications. 153 participants received either one of two doses of SEL-212 or a placebo via monthly IV infusions for about six months. The main goal was to see if the t…

This small, completed pilot study tested an experimental drug called pegcetacoplan in 12 adult patients. These patients developed a dangerous blood vessel complication called TA-TMA after receiving a stem cell transplant. The main goals were to understand how the drug behaves in …

This study tested a drug called emapalumab in children and adults with a dangerous immune system overreaction called Macrophage Activation Syndrome (MAS). MAS can occur in people with Still's disease or lupus who don't respond well to high-dose steroid treatment. The trial aimed …

This study looked back at the medical records of 32 Italian patients with Still's disease who developed a dangerous immune system complication. The goal was to understand how doctors treated this complication, how long it took patients to recover, and what their survival rates we…